Literature DB >> 26613820

A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.

Waleed El-khayat1, Ghada Abdel Moety2, Maged Al Mohammady2, Dalia Hamed3.   

Abstract

OBJECTIVE: To examine the efficacy of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone among women with polycystic ovary syndrome (PCOS) resistant to clomifene citrate.
METHODS: A prospective double-blind randomized controlled trial of women younger than 40 years who had primary/secondary infertility associated with PCOS and had not ovulated in response to clomifene citrate regimens previously was conducted at a center in Cairo, Egypt, between August 1, 2013, and December 31, 2014. Computer-generated random number tables and opaque envelopes were used to assign participants to group A or group B. Participants allocated to group A received 100mg clomifene citrate daily for 5 days from the third day of the menstrual cycle, whereas those in group B received 5mg letrozole daily in the same regimen. All patients received 850 mg metformin and 15 mg pioglitazone for 10 days from the first day of the menstrual cycle. The primary outcome was cumulative ovulation rate. Analyses were by intention to treat.
RESULTS: Fifty women were assigned to each group. Ovulation occurred in 108 (92.3%) of 117 cycles in group A and 93 (86.9%) of 107 cycles in Group B (P=0.184).
CONCLUSION: Combined treatment with letrozole, metformin, and pioglitazone was efficacious among women with PCOS resistant to clomifene citrate. ClinicalTrials.gov: NCT01909141.
Copyright © 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clomifene citrate; Clomifene citrate resistance; Letrozole; Metformin; Pioglitazone; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2015        PMID: 26613820     DOI: 10.1016/j.ijgo.2015.06.063

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  6 in total

Review 1.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

2.  Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway.

Authors:  Yuanyuan Wu; Pengfen Li; Dan Zhang; Yingpu Sun
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

Review 3.  Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.

Authors:  Sebastian Franik; Quang-Khoi Le; Jan Am Kremer; Ludwig Kiesel; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2022-09-27

4.  The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

Review 5.  Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.

Authors:  Sebastian Franik; Stephanie M Eltrop; Jan Am Kremer; Ludwig Kiesel; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2018-05-24

6.  Efficacy of clomifene citrate for the treatment of patients with polycystic ovary syndrome: A protocol of systematic review.

Authors:  Qin-Wei Han; Jin-Ping Wu; Ying Pang; Li-Xia Wu; Li-Na Yang
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.